

For personal use only

Creso Pharma Investor Presentation

ASX: CPH
OTC: COPHF
FRA: 1X8

September 2021



Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso.

This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision.

The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

To the maximum extent permitted by law, Creso, its related bodies corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including (but not limited to) any liability arising under the Australian Securities and Investments Commission Act 2001, Corporation Act 2001 or from the fault or negligence on the part of any person, for any loss arising from the use of the presentation or its contents arising in connection with it. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.



Company overview

For personal use only

Business description

- Founded in 2016 and ASX listed on 20 October 2016, trading under ASX code CPH
- Primarily based in Switzerland (R&D and marketing), with wholly owned cultivation in Canada and cultivation potential in Colombia
- Only ASX-listed company with 100% ownership over a Canadian Licensed Producer and an established psychedelic life sciences business
- Wholly owned subsidiary Mernova Medical Inc. generating revenues
- Innovative pharmaceutical-grade cannabis and hemp product portfolio across four categories and global distribution agreements in place
- Co-Founder Dr Miri Halperin Wernli is currently President of Mind Medicine Inc. (NEO:MMED, OTCQB:MMEDF, DE:MMQ) (Market Cap US\$1.2 billion¹)

Financial snapshot

	AUD
Share Price ¹	\$0.13
52-wk High	\$0.47
52-wk Low	\$0.024
Shares on Issue	1.196Bn
Market Capitalisation	\$155.6m
Total Debt Outstanding	Nil
Cash ²	\$15,970,317
Enterprise Value	\$167m

¹ As of September 8 2021

² As at 31st July

³ Once Mr. Linton's 30,000,000 options are exercised at \$0.039, held by Mr. Bruce Linton <THE LINTON FAMILY 2040 A/C>

Share price chart (AUD cents)¹



Ownership structure¹

Top 50 Shareholders	36.78%
Top 5 Shareholders	
ATLANTIC CAPITAL HOLDINGS PTY LTD <ATLANTIC CAPITAL A/C>	9.50%
Bruce Linton ³	5.5%
JAMBER INVESTMENTS PTY LTD <THE AMBER SCHWARZ FAM A/C>	4.61%
SUBURBAN HOLDINGS PTY LTD <THE SUBURBAN SUPER FUND A/C>	3.09%
BNP PARIBAS NOMINEES PTY LTD SIX SIS LTD <DRP A/C>	2.42%




Financial overview

H1 2021 results overview

For personal use only

CYTD group revenue: \$3,066,973	↑	98% ¹
Mernova revenue: \$1,722,291	↑	519% ²
Creso Swiss revenue: \$1,334,227	↑	11% ³
Cash position: \$15,970,317	↑	488% ⁴




1 Compared to H1 FY2020
2 Compared to H1 FY2020
3 Compared to H1 FY2020
4 Increase in cash compared to Q2 FY20



The Material Creso Group company structure

For personal use only



Board of Directors



Dr. James Ellingford
Executive Director

Dr. Ellingford's professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

Dr Ellingford holds a Post Graduate in Corporate Management, a Masters in Business Administration as well as a Doctorate in Management. Dr Ellingford also lectures MBA students in Corporate Governance at a leading Sydney University.



Boaz Wachtel
Co-Founder & Director

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publicly traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.

Mr Wachtel was part of the European Coalition for Just and Effective Drug Policies ("ENCOD") which was involved in driving the change in the UN classification of cannabis to a Schedule I substance in December 2020.



Adam Blumenthal
Co-Founder & Non-Executive Chairman
of Creso Pharma

Mr Blumenthal has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries. Using his experience and extensive network of international contacts to provide corporate advisory and capital markets input, he has successfully brought to market several companies and is actively involved in mining, cyber security, agricultural technology, medicinal cannabis, pharmaceutical and information technology sectors.

Mr Blumenthal holds a Bachelor of Commerce, Masters of International Relations and a Masters of Business Administration.



The Board is backed by a qualified Executive Team

For personal use only



William (Bill) Fleming

President & CEO of Halucenex

Mr. Fleming has founded and served as CEO of a number of entrepreneurial companies, and has developed corporate strategies for family-owned businesses to multi-national companies. He is currently Executive Chairman of Mountain Lake Minerals and was recently President of Mernova Medicinal Inc. which recently sold to Switzerland based Creso Pharma Limited. Mr. Fleming is a Director of SpeakEasy Cannabis. He served as the CFO and Director of NWest Energy Corp.



Jack Yu

Mernova Managing Director

Mr Yu has 25 years of practical experience growing cannabis, including nine years consulting for licensed Canadian medicinal cannabis growers. Mr Yu previously worked for Canopy Growth Corp. (TSX:WEED, NYSE:CGC), the world's largest cannabis company by market cap, as Regional Production Manager for Eastern Canada. Prior to this, he was simultaneously the original Master Grower and Production Manager for MedReleaf Corp., now owned by Aurora Cannabis Inc (TSE:ACB).



Isaac Allen

Vice President Mernova

Mr Allen has significant expertise in optimising business operations from executive positions in industries spanning cannabis, insurance, technology and entertainment. He was formerly National Operations Process Improvement Manager at Canopy, where he developed and executed a number of business strategies and efficiency initiatives. He is also the Founder and former CEO of a disruptive insurance technology start-up and has held senior executive positions at various companies.



Jorge Wernli

Commercial/Market Access Director

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies Novartis, Wyeth, Vifor and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.



Dr. Gian Trepp

Commercial/Marketing Director

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.

He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.



Golan Hayat

Director Commercial Operations

Has 20 years of finance experience in the global pharmaceutical industry. Golan has led supply chain finance as well as treasury of leading global companies. He has worked previously as a CFO of a European genetic company



The Board is backed by a qualified Executive Team

For personal use only



Chris Hession

Director of Strategic Partnerships

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region.

He has held leadership positions with a number of multinational companies and introduced several new ingredients across the APAC region over this time.



Chris Grundy

Chief Financial Officer


Mr Grundy is a career CFO with over 30 years' commercial experience in the life sciences sector, in listed and large multi-national companies as well as early-stage, rapidly-growing businesses. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.



Micheline MacKay

Corporate Manager

Ms. MacKay brings over 20 years of experience in the Pharmaceutical and Medical Device industries working under strict GMP regulations. She has held leadership positions in the last five years and focused on driving the business to the next level by creating company vision, mission and values, and measuring metrics and key performance indicators.



Laura Serrano

Clinical Administrator

Laura has a BsC degree in Advertising and Public Relations from the University of Madrid and has years of experience in organizing events.

Since 2010 she has worked for different international companies in the sales and marketing field.

The Board is backed by a qualified Executive Team

For personal use only



Dr. Niall Buckley

Alternate QPIC

Canadian Practicing Physician for over 30 years family practice and experience in Veterans PTSD. National University of Ireland, UCC BSc (Hons), MB BCh BAO Human Physiology and Medicine Activities and Societies: College of Physicians and Surgeons of Nova Scotia. College of Family Practice of Canada. Fellowship Anti-Aging Medicine.




David James

Halucenex Chief Science Officer & Qualified Person in Charge

David has a PhD in Chemistry from Memorial University and a BSc from Dalhousie University.

David has 7 years in quality assurance, consulting and analytical testing in the cannabis industry. In 2013, he served as the quality assurance person for an up-and-coming licensed producer in Edmonton, Alberta. In 2017, he moved back to the east coast and opened up Nova Scotia's only Health Canada approved Cannabis quality assurance testing laboratory at Perennia Food and Agriculture. He has served as the laboratory director of the lab since its inception.



Sarah Widmer

Group Product Manager

Sarah has a M Sc BA with Major in Marketing at the University of Bern. During her extended stay in Australia, she also completed a Certificate IV in Accounting at AIPE, Sydney. She started as Junior Product Manager at Creso. She held the positions of Marketing Planning & Promotion Assistant at Douglas Perfumes and Administration Supervisor at Dynamite PR Agency.



Don Hunter

Halucenex SVP Business Development & Strategic Partnerships

With over 30 years of entrepreneurship and corporate development Don has established an expansive network in the healthcare, bio science, cannabis, and the green tech sectors.

These years of experience has given him the invaluable resources to excel at driving companies to positive revenue, onboarding key partnerships, raising capital, and leading healthcare teams throughout various phases of operations. Don has been instrumental in a number of public offerings amounting to almost a billion dollars in market caps and continues to focus on disruptive intellectual properties, technologies and science that bring good will and well being to the global markets.



Bruce Linton – Strategic Advisor to Creso Pharma

World leading cannabis executive and Canopy Growth Founder joined Creso Pharma as a Strategic Advisor



Mr Linton sees potential in **Creso Pharma's IP, established global distribution footprint and robust product pipeline in distinct product categories.**

As Strategic Advisor, Mr Linton will leverage his connections, expertise and influence to consult with Creso Pharma Board to shape its long-term business strategy.



- Led Canopy Growth Corporation (TSX:WEED, NYSEWE:CGC) from startup to US\$17 billion market cap on the NYSE during his six year tenure
- MindMed (Market Cap \$1.28 billion¹)
- Sits as Executive Chair of Gage Cannabis Co., and Director of Mind Medicine Inc. (NEO:MMED, OTCQB:MMEDF, DE:MMQ). Also Co-Chairman and former CEO of tech company Martello Technologies Group Inc. (CVE:MTLO) and Co-Founder of Ruckify Software.

¹ Market cap in CAD as at 07/09/21



Dr. Miri Halperin Wernli – Strategic Advisor to Creso Pharma

Leading pharmaceutical executive with over 25 years of strategic and operational leadership in global drug development



Dr. Halperin Wernli will utilise her **extensive experience** and leverage leading networks in the biopharmaceutical industry to drive overall **business growth** and **unlock opportunities** in product development and commercialisation.

As a strategic advisor, Miri will assist in **product development, commercialization, R&D and strategic marketing** to expedite Creso Pharma's growth as it enters more lucrative markets.

- Dr. Halperin Wernli was an original founder of Creso Pharma and was instrumental in scaling the company's operations since 2015
- Prior to Creso Pharma, Dr. Halperin Wernli held senior leadership positions in Europe and the US with Merck, Sharpe and Dohme, Roche and Actelion Pharmaceuticals
- Dr. Halperin Wernli is currently the Executive President and Director of MindMed, one of the world's largest psychedelic companies.
- MindMed (Market Cap \$1.28 billion¹)



¹ Market cap in CAD as at 07/09/21

William Lay– EVP – Strategy, Origination & Operations

Leading cannabis executive with over \$5Bbn of cannabis M&A transactions joins Creso Pharma as a EVP & Chief Strategic Officer



Will is an experienced M&A and corporate strategy professional with an extensive investment banking background. **Will has led over C\$5bn of cannabis M&A transactions**, including leading the largest acquisition in the history of the cannabis sector. Will spent two years with Canopy Growth reviewing and executing numerous global cannabis transactions.



- Spent two years at Canopy Growth Corporation (TSX:WEED, NYSEWE:CGC) as an Associate Director where he executed multiple cross-boarder transitions while working with internal teams on various corporate strategy initiative




- Spent over two years at leading Canadian investment Bank BMO Capital Markets as an investment banking Analyst
- During his time at BMO Will worked in both the London and Toronto offices where he worked on various M&A transactions across jurisdictions and industries



Geographically diversified and vertically integrated

For personal use only



The Creso Group Partners



24,000 sq. ft cultivation facility

Creso Pharma Switzerland GmbH
Human & Animal CBD Products

HALUCENEX
life sciences inc.
Psychedelics Division



For personal use only

The Creso Group key licenses and regulations



24,000 sq. ft cultivation facility



Recreational and Medicinal Licence

- Creso Pharma's wholly-owned subsidiary Mernova possesses a sales license endorsed by Health Canada that allows it to sell cannabis products for both medicinal and recreational purposes

Creso Pharma Switzerland GmbH
Human & Animal CBD Products



Quality Swiss Products Developed Under the Well Regarded EU Framework

- Creso's products manufactured in Switzerland are veraciously scrutinised through the highly regarded EU regulatory framework, ensuring high quality products



Psychedelics Division



Controlled Drugs and Substances Dealer's Licence

- The controlled drugs and substances dealer's licence allows Halucenex to possess, sell, transport and conduct R&D on a broad range of psychedelic substances including psilocybin, ketamine, LSD and MDMA
- Licence significantly increases scope of work in regards to psychedelics and is expected to **fast track phase II clinical trials** to test psilocybin on treatment resistant PTSD



Mernova Medical Inc.

For personal use only



Mernova medicinal subsidiary overview

100% owned revenue-generating Canadian LP in advanced stages of securing EU GMP certification

Strategically located

- Established facilities in Nova Scotia, Canada, 69 km to Halifax and Halifax Stanfield Int airport
- Optimally located to supply Canadian, US and European markets
- Proximity to the U.S border (approx. 240km from the US border)

World class facilities

- 24,000 sq. ft. facility purpose built to Health Canada GPP standard, scalable to 200,000 sq. ft.
- License to cultivate, process, and sell cannabis to provincial and territorial markets, and for medical purposes
- Fully automated climate control and irrigation
- 10 grow rooms with total production of 1,200-1,400 kg/year with potential to produce 4,000kg

EU GMP Certification in advanced stages

- Working on securing EU GMP certification – licence to sell GMP products in the EU
- Once EU GMP certification is received, Mernova will be one of only a small number of Canadian LPs with a licence to export to the EU

Revenue generating

- First sales to the Canadian domestic market commenced July 2019
- Began Retail Sales September 2020. Mernova's Ritual Green products (Dried Flowers) are available for sale in Nova Scotia, Yukon, New Brunswick and Ontario
- Mernova's Ritual Sticks (Pre-rolled Joints) products are available for sale in Nova Scotia, the Yukon, New Brunswick and Ontario
- Mernova's Ritual Black (Hash) products to launch in Q1 2022



Mernova Medicinal Inc.
Nova Scotia



Mernova management

Ex-Canopy Growth Corp. executives appointed to senior management team, and experienced cultivation and sales staff



Jack Yu, Managing Director

Mr Yu has 25 years of practical experience growing cannabis, including nine years consulting for licensed Canadian medicinal cannabis growers. Mr Yu previously worked for Canopy Growth Corp. (TSX:WEED, NYSE:CGC), the third largest cannabis company by market cap, as Regional Production Manager for Eastern Canada . He also held the role of Interim Cultivation Manager for Canopy's Newfoundland, Edmonton and Scarborough facilities. Prior to this, he was simultaneously the original Master Grower and Production Manager for MedReleaf Corp., now owned by Aurora Cannabis Inc (TSE:ACB). He has also consulted for applicants seeking Health Canada licenses to cultivate and distribute medicinal cannabis.



Isaac Allen, Vice President

Mr Allen has significant expertise in optimising business operations from executive positions in industries spanning cannabis, insurance, technology and entertainment. He was formerly National Operations Process Improvement Manager at Canopy, where he developed and executed a number of business strategies and efficiency initiatives. He is also the Founder and former CEO of a disruptive insurance technology start-up and has held senior executive positions at various companies.



Mernova's mission

Ex-Canopy Growth Corp. executives appointed to senior management team, and experienced cultivation and sales staff

At Mernova, our priority is quality

- We do whatever it takes to produce the best product possible.
- We respect both the product and our discerning customers, and that is why our processes are done by hand, including trimming and packaging for our Ritual Green brand of dried flower
- Mernova received a designation for Craft Cannabis by Ontario Cannabis Store for its high-quality products

As Mernova continues to scale up production according to its 3-phase plan, it has strengthened its senior management team with two Ex- Canopy Growth Corporation alumni



Product suite

Diverse product range sold throughout state owned provinces across Canada

Ritual Green

- Recreational craft cannabis brand Ritual Green successfully launched in Canada 2020
- Hydroponically grown indoors, hang-dried, hand trimmed and cured
- Received the craft Cannabis designation by state owned Ontario Cannabis Store (OCS)



Clementine Punch dried Flower produced by Mernova

Ritual Sticks

- Recently Launched and sold by state owned. Nova Scotia Liquor Corporation, Yukon, Cannabis NB and OCS
- Made from the same high-quality cannabis that is sold as dry flower under the Ritual green brand



Ritual Sticks product packaging and branding images

Ritual Black

- Our soon-to-launch Hash brand
- Hash is a chemical free, solventless extract
- Allows Mernova to utilize material that:
 - Is older, which is of benefit when making Hash, as like fine wine or whiskey, it improves with age



Hash produced by Mernova

Mernova's 2020 milestones

Mernova continued to progress its strategy to supply premium quality, artisanal cannabis and cannabis products in Canada



Commenced retail sales of Ritual Green Products

Mernova commenced retail sales of "Ritual Green", entering several territories:

- Nova Scotia
- Ontario
- Yukon
- New Brunswick

Mernova is working on getting registered in additional provinces: Saskatchewan, Nunavut, Alberta and British Columbia

Sales made to Ontario Cannabis Retail Corporation, formally recognizing Mernova as a supplier to Canada's largest recreational market

Recognized as a supplier in Ontario



Plan to Launch products into the Canadian Hashish Market

Mernova announced plans to diversify its product range with launch of new products in Q1 2021 to target the Canadian Hashish market



Mernova's 2021 milestones

Mernova continued to progress its strategy to supply premium quality, artisanal cannabis and cannabis products in Canada



Awarded Craft Cannabis designation

Mernova introduces fourteen new strains to support strong customer demand:

- High THC content (20-30%)
- Increase in product offering to grow market share and drive brand recognition
- Product range expansion positions Mernova to tackle US market



Secured medical cannabis sales license

Mernova recorded a \$966,459 in revenue for Q2 2021 – a 28% increase on the previous quarter, driven by:

- Multiple PO from province partners and returning customers
- Growing consumer demand, product development and expansion
- Purchase orders received for new Ritual Green products

Introduction of 14 new strains



Sales license allows Mernova to sell cannabis products for recreational and medicinal purposes

- License extension allows for Canada-wide, direct-to-patient sales, eliminating the need for provincial/territorial wholesalers
- Allows direct interaction with consumers and better product quality control

Consecutive quarter of record revenue growth



Mernova awarded craft designation by the Ontario Cannabis Store

- Mernova becomes one of the select group of licensed producers to be awarded Craft designation by the Ontario Cannabis Store (OCS) for its Ritual Green brand of dried cannabis flower
- The craft designation broadens visibility of products and create a competitive advantage



For personal use only

Creso Pharma Switzerland



Creso Pharma Switzerland

Creso Pharma's Swiss-based animal and human health **CBD** divisions achieved a number of significant milestones in 2020



Recovering momentum in animal and human health business impacted by COVID and regulatory changes

HoA signed with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance to supply to AU and NZ following legalisation of CBD

Commercial term sheet signed for entry into Scandinavian, Portuguese and Brazilian markets

LOI signed to enter Pakistan market with hemp therapeutics

LOI signed to enter Sri Lanka



New products finalized for commercial launch

Multiple large purchase orders received in 2020

- anibidiol® became first approved CBD hemp-based feed for pets in Latin America
- anibidiol® purchase orders from Uruguay \$89k Q1 2021
- POs received for anibidiol® in the EU worth A\$414k in Dec 2020
- Second PO received for cannamics (cannaQIX®) from partner in South Africa
- PO received for A\$320k from partner Pharma Dynamics, subsidiary of Lupin International (NYSE:LUPIN)
- \$247k POs for anibidiol® from Virbac in Jan 2021

Distribution agreements signed in new jurisdictions



Creso successfully developed and prepared new products for launch across animal health, human health divisions:

- anibidiol® EQUI – for equines
- anibidiol® hemp flour based
- cannaQIX® NITE
- cannAPEAL®
- cannAPEAL® NITE
- cannaQIX® Hemp Teas
- cannaQIX® hemp tea based
- cannaQIX® ORAL CARE




Innovative product delivery systems

Extensive product research and development with a focus on innovative methods of delivery

For personal use only

Bioavailability¹

How effectively medicine is absorbed



Buccal (Absorbed in mouth)




Topical (Targeted muscular absorption)




Buccal (Absorbed in mouth)



Sublingual (Under the tongue)



Transdermal (Through skin time release)



¹ Creso Pharma, Newmeyer MN, et al Clin. Chem. 2016 (<https://www.ncbi.nlm.nih.gov/pubmed/27899456/>), <https://shopatbloom.com/maryland/cannabis-bioavailability-whats-effective-method/>, <https://medium.com/@ericgeisterfer/the-bioavailability-of-medical-marijuana-6d05b712baa0>

Established products and branding

Creso Therapeutics

For personal use only



cannaQIX® 50

cannaQIX® 50 is a CBD based broad spectrum hemp extract product in innovative, buccal lozenge formulation with vitamins and minerals

- Non detectable THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain in humans
- Formulated in an innovative delivery system maximizing absorption



Medicinal CBD Oil

Medicinal CBD Oil is a high-grade therapeutic CBD oil

- 25ml 10% dropper
- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain in humans



Established products and branding

Creso Nutraceuticals


For personal use only



cannaQIX® 25

cannaQIX® 25 is a sugar free Food Supplement in innovative buccal formulation containing CBD from broad spectrum hemp oil extract, vitamins and minerals

- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets stress reduction and support of cognitive and psychological functions in humans
- Formulated in an innovative delivery system maximizing absorption



cannAPEAL®

cannAPEAL® is a sugar free Food Supplement in innovative buccal formulation containing organic hemp seed oil and vitamins

- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets healthy aging and supports stress reduction in humans
- Formulated in an innovative delivery system maximizing absorption



Established products and branding

Creso Nutraceuticals



cannaQIX® 10

cannaQIX® 10 is a CBD based hemp seed oil product in innovative, buccal lozenge formulation with vitamins and minerals*

- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Supports the management of stress
- Formulated in innovative delivery system maximizing absorption (patent filed)



- Follow-up product ready for launch: cannaQIX® 10 CBD hemp tea-based product in innovative buccal lozenge formulation with vitamins and minerals



Products ready for launch

Creso Nutraceuticals

For personal use only



cannaQIX® Hemp Tea a hemp based instant tea to support immune and mental systems

- No THC
- Cannabis sativa plant material + vitamins in proprietary formula
- 7 g hemp material p/jar, 8mg CBD p/cup
- Broad spectrum entourage effect due to natural plant material base
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Addresses need to reduce stress and provide good feel



cannaQIX® NITE Hemp Tea is a hemp based instant tea is to support better sleep

- No THC
- Cannabis sativa plant material + vitamins + lemon balm in proprietary formula
- 7 g hemp material p/jar, 8mg CBD p/cup
- Broad spectrum entourage effect due to natural plant material base
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Addresses need to reduce stress and support good sleep



cannaQIX® Immunity Hemp Tea is a hemp based instant tea to support strengthening of the immune system

- No THC
- Cannabis sativa plant material + vitamins + special herb extracts + minerals in proprietary formula
- 7 g hemp material p/jar, 8mg CBD p/cup
- Broad spectrum entourage effect due to natural plant material base
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Addresses need to reduce stress and provide good feel



Established products and branding

Creso Animal Health

For personal use only



anibidiol®

anibidiol® 2.5 and 8 are CBD hemp oil-based Complementary Feed products for companion animals with CBD from broad spectrum hemp oil in an innovative granular buccal formulation for pets

- No THC
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets stress and the strengthening of the immune system
- Formulated in a pet specific innovative delivery system



anibidiol® EQUI & SWINE products

- 250 g grinded hemp plant material in a 750ml jar
- Apple and neutral taste
- THC < 0.2%
- GAP compliant
- Distributed by veterinarians
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Targets chronic pain and the strengthening of the immune system
- Formulated in a pet specific innovative delivery system



Established products and branding

Creso Topicals /Cosmetics

For personal use only



cannaDOL®

cannaDOL® is a CBD-based functional topical with essential oils

- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Addresses the analgesic need in sports-related muscle injuries, arthritis and osteoarthritis



cannaQIX® ORAL CARE

cannaQIX® ORAL CARE is a sugar free Oral Cosmetic in innovative buccal formulation containing CBD, mint, and sage

- Box of 30 lozenges with 10mg CBD and 25mg CBD
- No THC
- Produced in a certified GMP compliant facility and with “Swiss Made” Label
- Helps restore oral health – reducing inflammation and supporting the cultivation of healthy oral bacteria
- Formulated in an innovative delivery system maximizing absorption



For personal use only

Halucenex Life Sciences inc.



Halucenex Life Sciences inc.

Company overview



Halucenex is a life sciences development company with a focus on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.

Halucenex operates a 6,000 square foot medical facility, with 6 treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research.

The facility is strategically located on a 160,000 sq ft lot adjacent to The Hants Community Hospital in Windsor, Nova Scotia, and which specialises in the treatment of mental health conditions.

The facility includes a Controlled Substances Laboratory and 18 treatment rooms dedicated to performing psychedelic-assisted psychotherapy and clinical research in micro and macro dosing.



Treatment Facility in Nova Scotia



Hants Community Hospital



Halucenex Laboratory Setup



Halucenex is positioned to lead innovation in the psychedelics inspired medicines space

For personal use only

With its dealer's licence, Halucenex is fully licensed with access to a medical facility optimally located and fit for conducting clinical trials

Aiming to be one of the only fully vertically integrated Canadian providers of Psychedelic-Assisted Psychotherapy

Supply secured from Canada's only pharmaceutical-grade psilocybin producer

Fast track to early revenue generation

Large and emerging market opportunity

Controlled Drugs and Substances Dealer's Licence allows for research and development of psilocybin, LSD and MDMA
Halucenex operates a 6,000 sq. ft. medical clinic facility in Nova Scotia, Canada, next to an Emergency hospital with 18 treatment rooms

Controlled Substances License and CTA Permit under application – once granted, Halucenex will be one of the only companies operating entirely out of Canada

Synthetic psilocybin supply secured from Psygen, guaranteeing supply and availability for defined clinical trial program

Halucenex has strategic affiliations with Veterans Affairs Canada and Veteran Support Groups via Adviser David Fraser – provides a fast route to a market with major demand Halucenex to target treatment of Treatment Resistant Depression and Anxiety

The economic burden of mental illness in Canada is estimated at C\$51Bn¹, while COVID-19 has worsened the global mental health crisis. More than 340m people suffer from mental illness globally – current available treatments for mental illness have limited effectiveness and many side effects

¹ Centre for addiction and Mental Health (2018). Mental Illness and Addiction: Facts and Statistics. [online] CAMH. Available at: <https://www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics>.



Halucenex executive board

For personal use only

Strong track record of commercializing alternative medicines and extensive experience working with Veterans and the Canadian Veterans Affairs Department



William (Bill) Fleming, President & CEO of Halucenex

Mr. Fleming has founded and served as CEO of a number of entrepreneurial companies, and has developed corporate strategies for family-owned businesses to multi-national

companies. He is currently Executive Chairman of Mountain Lake Minerals and was recently President of Mernova Medicinal Inc. which recently sold to Switzerland based Creso Pharma Limited. Mr. Fleming is a Director of SpeakEasy Cannabis. He served as the CFO and Director of NWest Energy Corp.

Mr. Fleming has experience raising equity for small cap companies and has experience in mineral exploration, renewable energy, cannabis and the psychedelic industry.



Major-General (Ret.) David Fraser, Clinical Advisor to Halucenex

Major-General (Retired) David Fraser is one of Canada's most accomplished leaders in both the public and private sectors. He is the President of AEGIS Six Corporation and sits on several boards. David Fraser served for over 31 years with the Canadian Armed Forces. Joining the Second Battalion Princess Patricia Canadian Light Infantry (PPCLI), his career is highlighted by numerous operational tours around the world. He has served in command at every rank from lieutenant to major-general on operations commanding Canadian and multi-national troops.

For his leadership he is one of the most decorated officers Canada has produced. He has been recognized for his leadership by the United States twice (Legion of Merit and Bronze Star), NATO, the Netherlands, Poland, the Atlantic Council and Canadian Defence Academy as a Vimy recipient. He is the recipient of the Commander of Military Merit, the Meritorious Service Cross, and Meritorious Service Medal from Canada.



Don Stewart, Advisor to Halucenex

Dr. Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. He is also the founder and President of Alba Biologics Group. Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs; supervised animal efficacy and toxicology studies as well as clinical trial programs; and obtained more than \$15 million in external grant and contract funding over a five-year period.

Dr. Stewart has a PhD in biochemistry from the University of London in the U.K. He has given numerous lectures at international symposia on research management, manufacturing strategies and biosimilar pharmaceuticals.

Halucenex executive board

For personal use only

Strong track record of commercializing alternative medicines and extensive experience working with Veterans and the Canadian Veterans Affairs Department



Don Hunter SVP, Halucenex Business Development and Strategic Partnerships

With over 30 years of entrepreneurship and corporate development Don has established an expansive network in the healthcare, bio science, cannabis, and the green tech sectors.

These years of experience has given him the invaluable resources to excel at driving companies to positive revenue, onboarding key partnerships, raising capital, and leading healthcare teams throughout various phases of operations. Don has been instrumental in a number of public offerings amounting to almost a billion dollars in market caps and continues to focus on disruptive intellectual properties, technologies and science that bring good will and well being to the global markets.



David James, Halucenex Chief Science Officer & Qualified Person in Charge (QPIC)

David has a PhD in Chemistry from Memorial University in St. John's Newfoundland and a BSc from Dalhousie University.

David has 7 years in quality assurance, consulting and analytical testing in the cannabis industry. In 2013, he served as the quality assurance person for an up-and-coming licensed producer in Edmonton, Alberta. In 2017, he moved back to the east coast and opened up Nova Scotia's only Health Canada approved Cannabis quality assurance testing laboratory at Perennia Food and Agriculture. He has served as the laboratory director of the lab since its inception.

What is psychedelic-assisted psychotherapy?

What are psychedelics?

Psychedelics (also known as hallucinogens) are a class of psychoactive substances that produce changes in perception, mood and cognitive processes¹

Psychedelics affect all the senses, altering a person's thinking, sense of time and emotions. They can also cause a person to hallucinate – seeing or hearing things that do not exist or are distorted.

There are many different kinds of psychedelics. Some occur naturally, in trees, vines, seeds, fungi and leaves. Others are synthetic and made in laboratories.

Psychedelics are known to be able to treat disorders such as:

- Depression
- Anxiety
- Eating disorders
- Substance addition




¹ Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews*, 68(2), 264-355. <https://doi.org/10.1124/pr.115.011478>

Halucenex's three-tiered strategy

A defined, three-tiered strategy to become a fully vertically integrated provider of psilocybin and psychedelic assisted psychotherapy to revolutionise the treatment of mental illnesses

For personal use only



Becoming A Clinical Drug Pipeline Provider of Psychedelic-Assisted Psychotherapy

Halucenex is aiming to complete a Phase 2 clinical trial testing the effects of psilocybin on Treatment Resistant Depression in Veterans suffering Post Traumatic Stress Disorder.

Accelerated path to commercialization via affiliation with Veterans Affairs Canada.

Halucenex will move to Phase 3 clinical trials with a larger, broader client base once post efficacy is demonstrated.

Research Into Interactions Between Synthetic Psilocybin & Natural Magic Mushrooms

Under the permitted terms of its Controlled Substances License, Halucenex will cultivate natural magic mushrooms and undertake extraction of a number of psychedelic derivatives

Halucenex will perform further testing of potential entourage effects between natural and synthetic psilocybin to develop further IP.

The Development of a Proprietary Synthetic Psilocybin Formulation

Under it's Controlled Substances License and in collaboration with non-profit organization Mitacs and Acadia University, Halucenex is developing core IP around a proprietary formulation of synthetic psilocybin to de-risk supply, increase yields for future micro and macro dosing formulations, and to open the manufacturing vertical.

The problem

Currently available treatments for mental health often have limited effectiveness and many side effects¹

The current available treatments use a combination of skilled therapists, support groups and medication. However, there is limited, timely access to these resources in a matter coinciding with the patient's treatment needs.

Too often, patients can only access one of these therapies which results in less-than-satisfactory outcomes. This applies especially for patients with drug-resistant conditions for whom traditional medications are often ineffective or trigger adverse side effects.

Psychedelic-Assisted Psychotherapy is a new alternative treatment that has shown promise in previous studies.




¹ Star*D Study

The problem

Current approaches to mental health treatments are outdated and ineffective

The number of people suffering from mental health illnesses continues to grow, with more than 264 million people suffer from depression globally²

Number of people diagnosed with mental health disorders globally¹



¹ Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018.

² World Health Organization. 2001. The World Health Report 2001: Mental Disorders affect one in four people

The market for treatments targeting mental illness

COVID-19 is further accelerating the urgent need for effective mental health treatments

The global pandemic has cost the Victoria and NSW an estimated A\$1bn from the most recent 2 month lockdown due to a rise in mental health problems²

Former Mental Health Commissioner Professor Hickie, has labelled the mental health crisis as a “shadow pandemic”


- Hospitalisation because of suicidal thoughts or self-harm has jumped 47% for people aged 12-17
- Lifeline recording busiest days in its 57-year history
- 5 year modelling projects a A\$100bn lost in productivity due to mental health issues

Global lockdowns induced by COVID-19 has led to increased mental health diagnosis in both the general public and frontline workers¹

- Critical mental health services have been disrupted or halted in 93% of countries worldwide while the demand for mental health services is increasing, highlighting the urgent need for alternative therapies

COVID-19's Strain on Mental Health³

US Adults Reporting Symptoms of Anxiety or Depression




July 2020




July 2019

UK Adults Reporting Symptoms of Anxiety or Depression



July 2020



July 2019

¹ World Health Organization, 2020. The impact of COVID-19 on mental, neurological and substance abuse issues: results of a rapid assessment

² Australian Financial Review, latest lockdown add \$1b to mental health “shadow pandemic”, 22/08/21

³ Office for National Statistics (UK Data); Centers for Disease Control and Prevention (US Data)

The market for PTSD treatment

The number of people suffering from Post-Traumatic Stress Disorder is also growing

For personal use only

Post-Traumatic Stress Disorder (PTSD) is a psychological reaction that manifests itself after a traumatic event

- 3.4% of the global population was diagnosed with PTSD in 2017¹
- Increases in occurrences of sexual relationship violence, interpersonal violence and exposure to organised violence have all led to rising numbers of PTSD¹
- Occurrences were twice as common in women than they were in men¹

Increases in 'traumatic events' globally have contributed to the rise of PTSD²

- It is estimated that about 8% of Canadians who experience a traumatic event develop PTSD³

¹ Oxford Martin School, 2017

² Sareen, 2021

³ Canadian Mental Health Association, 2013

The solution

- Psychedelic-Assisted Psychotherapy has produced impressive clinical outcomes for individuals suffering from mental health illness such as Post Traumatic Stress Disorder (PTSD), depression and anxiety
- A 2010 study showed that psilocybin reduced anxiety and depression in patients with advanced-stage cancer, helping them better cope with the fear of death¹
- A 2014 study suggested psilocybin could help with addiction: 80 percent of participants remained nicotine-free six months after receiving three psilocybin

NYU Langone Health establishes centre for psychedelic medicine

- MindMed recently partnered with NYU Langone Health and the NYU Grossman School of Medicine to establish a one-of-a-kind \$10 million centre that will accelerate research and physician training in the field of psychedelic medicine, focusing on psychiatry, medicine and preclinical research – supporting basic science to phase III clinical trials²



1 <https://www.abc.net.au/triplej/programs/hack/proposal-to-treat-mental-illness-with-magic-mushrooms-and-mdma/12622680#:~:text=Advocates%20say%20psychoactive%20substances%20could,with%20the%20fear%20of%20death>
2 <https://nyulangone.org/news/nyu-langone-health-establishes-center-psychedelic-medicine>

Market opportunity for psychedelic-assisted psychotherapy


For personal use only



\$100b

Estimated market for psychedelics medicines


cg/Canaccord
Genuity



264m

Number of people who suffer depression globally


World Health Organization



\$4.2b

Aggregate market cap of psychedelic drug companies

yahoo!
finance



2 in 3

Veterans suffer from PTSD

HEROIC MISSION
HONORABLE PASSION
DEDICATED RESPECT
DUTY ALWAYS
SERVICE COUNTRY
READY DEFEND
COMMITMENT
COURAGEOUS
INTEGRITY
VALIANT

Cohen Veterans Network



1 in 4

People in the world are affected by mental health disorders

World Health Organization

All figures in USD unless specified otherwise



Psilocybin used in psychedelic-assisted psychotherapy

Halucenex is working to advance the scientific understanding of microdosing for clinical purposes


Psychedelic-assisted psychotherapy involves administering microdoses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms, over two or three sessions of anywhere up to 10 hours.

- A macrodose is considered to be a dosage around 22 mg/70 kg.
- A microdose can range anywhere from (1 or 3 mg/70 kg).

Synthetic psilocybin is preferred in a clinical setting

Natural psilocybin is less compatible in clinical settings due to inconsistency of potency and therefore dosage.

Health Canada approves clinical trials only if companies have access to synthetic psilocybin to ensure consistency of dosage and purity in formulations.



Prototype of Halucenex micro and macro dosing packaging

Halucenex is fully licensed to commence clinical trials

For personal use only



Controlled Drugs and Substances Dealer's Licence Awarded

Controlled Drugs and Substances License (Dealer's License): permits the possession and research and development of psilocybin, LSD and MDMA

- Halucenex is one of only three public Canadian companies to hold a Dealer's License (Numinus (TSXV:NUMI) & Filament Health Corp (FH.NE))
- Halucenex will have a 10kg allowable possession of psilocybin under the Dealer's License
- Halucenex will have complete control over the R&D process without having to rely on universities, many of which have been disrupted due to COVID-19
- Competitors are dependent on partnerships with Universities to complete R&D on psychedelics



Clinical Trial Application to be Submitted

Clinical Trial Application (CTA) expected to be submitted to Health Canada by end October 2021

Halucenex 2021 achievements

Halucenex well positioned to be global leaders of psychedelic medicines



**Creso Pharma
Acquires Halucenex**

Creso Pharma completes the acquisition of established Canadian psychedelics company Halucenex Life Sciences Inc

- Provides Creso Pharma access to the emerging global market for psychedelic medicines estimated to be worth up to US\$100bn¹
- Halucenex to progress phase II clinical trial to test the efficacy of psilocybin when used to treat Post Traumatic Stress Disorder (PTSD)
- Creso Pharma becomes the only ASX listed company, and one of the few globally. Operating in Cannabis and Psychedelic R&D and therapies and treatments

Halucenex Life Sciences Inc. enters MOU with Landing Strong for follow up support for clinical trial participants.

- Landing Strong provide structured support for military members, first responders and veterans
- Will provide an option for post clinical trial support and workplace integration programs for phase II clinical trial patients
- Landing Strong funding partners include Veterans Affairs Canada, Nova Scotia Mental Health Foundation, ACOA and branches of the Nova Scotia government

**Halucenex enters
MOU with Landing
Strong**



**Health Canada award Halucenex
the Controlled Drugs &
Substances Dealer's License**

License allows Halucenex to possess, sell, transport, and conduct R&D on a broad range of psychedelic substances

- Halucenex one of the only few companies globally with a dealer's license
- License increases the scope of work regarding psychedelics and expected to fast track phase II clinical trials
- Unlocks lucrative psychedelic drug market expected to reach US\$6.8bn by 2027¹



¹ <https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market>

Halucenex Q4 2021-Q1 2022 milestones

Halucenex well positioned to be global leaders of psychedelic medicines

For personal use only



USP 61 and USP 62 Testing Finalized

- USP 61 and USP 62 validated for aqueous solution
- Stability study has commenced 7 and 14 days
- Psilocybin clinical protocol being finalised

Recruitment for clinical trials will consist of patients from:

- veteran support groups
- physician and psychiatry clients

Clinical trial recruitment



CTA authorization

- 30-day review by Health Canada to receive no-objections letter
- Once no-objections letter is received a 20-day review by the Nova Scotia Ethics Committee approval will be conducted before commencing clinical trial client intake

Nanogel Product

Psilocybin formulation development based on nanoemulsion and nanoencapsulation

Product development initiatives



1 <https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market>

Agreement with Psygen

Access to one of the largest supplies of synthetic psilocybin in Canada

Psilocybin remains a Schedule I drug in most countries, however demand for research and clinical use is at all time highs

Psygen

Supply of pharmaceutical-grade synthetic psilocybin has been restricted due to:

- High barriers to entry prevent new players from supplying the market
- Lack of expertise in psychedelic medicinal chemistry
- Long lead time to obtain a license to produce restricted drugs
- High cost of building GMP compliant manufacturing facilities

Agreement signed with Psygen Industries Ltd

- Guaranteeing supply of 21.6 grams of high quality, GMP grade synthetic psilocybin, an amount sufficient to take Halucenex up to conclusion of its Phase 3 Trial with immediate availability for Phase 2 Trials
- Psygen is the only pharmaceutical-grade psilocybin producer in Canada
- Halucenex is one of only 11 companies to secure supply from Psygen

Canadian Veterans affiliation

Affiliation will provide a fast track to early revenues

For personal use only



Canadian Veteran Population

Strategic affiliations with Veteran Affairs Canada and Veteran Support Groups via Veteran Advisor David Fraser, retired NATO General, provides access to a market with major demand



Canadian Government budgeted over 10 years to support Research on Veteran Health

Canadian Veterans are at double the risk of mental illness compared to the general Canadian population, according to population studies



Veterans Affairs Canada spend on Disability Pensions in 2019

Halucenex will initially focus on the treatment of Treatment Resistant Depression in veterans, and aim to expand treatment to the general population and other mental illnesses

Halucenex Life Sciences inc.

Phase II Clinical Trial

Fast Tracked Phase II Clinical Trials

Clinical trials to test the efficacy of psilocybin on treatment-resistant post-traumatic stress disorder (PTSD)

Considerable progress has been made towards the trial, including securing several key partnerships allowing for patient recruitment, post trial care and initial testing of its psilocybin product, unlocking Halucenex to a lucrative market, estimated to be worth up to US\$25bn by 2025¹.

Phase II progress:

- Controlled Drugs and Substance Dealer's License from Health Canada
- All USP 61 test work completed with USP 62 protocols underway
- Clinical trial application lodgement to be expedited
- Operations located near some of Canada's largest army and naval bases



¹ Credence Research PTSD Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2018-2026

Halucenex's Long-term strategy

For personal use only



Clinical trials

Clinical trials will focus on the treatment of anxiety and other mental health challenges such as depression and PTSD



Developing IP for a formulation of synthetic psilocybin

Natural psilocybin is less compatible in clinical settings due to inconsistency of potency and therefore dosage, producing synthetic psilocybin in-house will replace third-party supply agreements and potentially allow Halucenex to supply to other distributors and practitioners



Delivery methods

Halucenex plans to develop products across a range of delivery methods such as psilocybin-infused capsules and tinctures



Agile business plan

Fast track to commercialisation via the Veterans market will deliver cash flow early, while maintaining a flexible business plan will allow the company to adapt to the changing regulatory environment

Comparable clinical programs

Company name	Psychedelic drug	Lead project indication	Clinical trial phase	Progress	Stock exchange	Market cap ¹
MAPS	MDMA	Post-traumatic stress disorder (PTSD)	Phase 3	Underway	Non-profit organisation	Nil
Compass Pathways	Crystalline Psilocybin	Treatment-resistant depression (TRD)	Phase 2	Underway	Nasdaq	\$1.2Bn CAD
Usona Institute	Psilocybin	Major Depressive Disorder (MDD)	Phase 2	Underway	Non-profit organisation	Nil
Cybin Inc.	Psilocybin	Major Depressive Disorder (MDD)	Phase 2a	Planning	NEO exchange	\$384M CAD
Mindmed	LSD	Anxiety	Phase 2	Planning	Nasdaq	\$1.2Bn CAD
Incannex	Psilocybin	Anxiety	Phase 2a	Planning	ASX	\$460m AUD
Creso Pharma	Psilocybin	Treatment-resistant PTSD	Phase 2	Planning	ASX	\$147m AUD

¹ Market cap as at 23/08/2021

For personal use only

Industry outlook

Path towards Federal legalization of Cannabis in United States

- Further states within North America legalizing cannabis and cannabis products
- House passed legislation H.R. 365 – Marijuana 1-to3 Act of 2021
- In the US cannabis is legal in 18 states and medical marijuana is legal in 37 with 5 more voted to legalize cannabis in November¹
- Once cannabis is legal on a federal level within North America, cannabis companies will be able to sell products in the US, access to financial products such as banks, loans, and major stock exchanges such as NASDAQ and NYSE

Widespread recognition of psychedelic medication to treat mental illness

- Of the 110,000 respondents worldwide to the Global Drug Survey, 6,500 people reported to have self medicated using psychedelics such as LSD, MDMA and psilocybin
- According to the global drug survey 86% of respondents suffering from mental health issues found that supervised psychedelic sessions reported the session was helpful

Market growth rates


- THC Canada 2026: C\$9bn (19% CAGR)
- THC US 2025: US \$41bn (16% CAGR)
- CBD Europe 2026: US\$26bn (45% CAGR)
- CBD US 2028: \$13bn (21% CAGR)
- Psychedelics North America 2027: US\$6.8bn



¹ <https://www.businessinsider.com.au/legal-marijuana-states-2018-1?r=US&IR=T#:~:text=Marijuana%20is%20legal%20for%20adults,and%20Connecticut%20legalized%20recreational%20cannabis.>

US progressing towards national legalisation of cannabis

For personal use only



Creso Pharma to Pursue NASDAQ & ASX Dual listing


NASDAQ listing provides vehicle into North American opportunities

Dual listing expected to unlock additional value for shareholders

- NASDAQ listing provides access to deeper pool of North American retail and institutional investors
- Targeting NASDAQ listing during H1 CY2022
- May allow potential revaluations of Creso Pharma in comparison to North American peers in the cannabis and psychedelic sectors
- Advance US growth focused opportunities across all operating divisions
- Favorable regulatory changes in the US cannabis and psychedelic industry will potentially provide an ideal operating landscape to pursue strategic growth opportunities

EAS Advisors mandated to expedite NASDAQ listing process

- EAS Advisors has participated in over US\$6.5Bn in successful transactions
- EAS founded by Edward Sugar, ex MD of Jefferies, who has vast experience in dual listings including cannabis & Psychedelic industry



Dual NASDAQ/NYSE and ASX Listed Companies

Company name	Stock Code	Stock exchange	Market cap ¹	Industry
BHP Billiton	BHP	NYSE	\$154Bn USD	Mining
Piedmont Lithium	PLL	NASDAQ	\$1.2Bn USD	Mining
Immutep Limited	IMMP	NASDAQ	\$328.4m USD	Biotech
James Hardie Industries	JHX	NYSE	\$18.1Bn USD	Industrials
Opthea Limited	OPT	NASDAQ	\$336.9m USD	Biotech
Square/Afterpay (Proposed)	SQ	NYSE	\$124Bn	Fintech

¹ Market cap as at 6/09/2021

Appendix 1

Major global cannabis industry players

Company name	Stock Code	Stock exchange	Market cap ¹
Aurora Cannabis	ACB	Nasdaq	\$1.77Bn USD
Curaleaf Holdings	CURA	CNSX	\$10.41Bn CAD
Canopy Growth	CGC	TSE	\$8.72Bn USD
GrowGeneration	GRWG	NASDAQ	\$1.89B USD
Tilray Inc	TLRY	NASDAQ	\$6.08Bn USD
Creso Pharma	CPH	ASX	\$147m AUD

¹ Market cap as at 23/08/2021

For personal use only



Cannabis innovation in the science of life – for people and pets

Creso Pharma Limited (ASX:CPH)

Australia

Suite 5 CPC, 145 Stirling Hwy
Nedlends WA 6009

Switzerland

Allmendstrasse 11
6310 Steinhausen , Schweiz

Canada

59 Payzant Dr
Windsor, Nova Scotia, B0N 2T0

Canada

50 Ivey Ln,
Windsor, NS B0N 2T0

www.cresopharma.com

Media enquiries

Ben Jarvis
Six Degrees Investor Relations
ben.jarvis@sdir.com.au
+61 (0) 413 150 448

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0) 431 271 538

Investor enquiries

Creso Pharma
+61 (0) 497 571 532
info@cresopharma.com

You can now text your queries
on +61 497 571 532

